250 related articles for article (PubMed ID: 32627087)
1. Application of PET Tracers in Molecular Imaging for Breast Cancer.
Boers J; de Vries EFJ; Glaudemans AWJM; Hospers GAP; Schröder CP
Curr Oncol Rep; 2020 Jul; 22(8):85. PubMed ID: 32627087
[TBL] [Abstract][Full Text] [Related]
2. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
3. Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer.
Ulaner GA; Vaz SC; Groheux D
PET Clin; 2024 Apr; 19(2):147-162. PubMed ID: 38177052
[TBL] [Abstract][Full Text] [Related]
4.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
5. PET Imaging for Breast Cancer.
Fowler AM; Cho SY
Radiol Clin North Am; 2021 Sep; 59(5):725-735. PubMed ID: 34392915
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
7. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
8. Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.
van Es SC; Venema CM; Glaudemans AW; Lub-de Hooge MN; Elias SG; Boellaard R; Hospers GA; Schröder CP; de Vries EG
J Nucl Med; 2016 Feb; 57 Suppl 1():96S-104S. PubMed ID: 26834109
[TBL] [Abstract][Full Text] [Related]
9. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
10. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
11. Clinical Validity of 16α-[
van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
[TBL] [Abstract][Full Text] [Related]
12. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
13. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
14. Molecular Imaging of Abdominal Aortic Aneurysms with Positron Emission Tomography: A Systematic Review.
Baolei G; Can C; Peng L; Yan S; Cheng Y; Hui T; Minzhi L; Daqiao G; Weiguo F
Eur J Vasc Endovasc Surg; 2021 Dec; 62(6):969-980. PubMed ID: 34696984
[TBL] [Abstract][Full Text] [Related]
15. Breast PET/MRI Hybrid Imaging and Targeted Tracers.
Romeo V; Helbich TH; Pinker K
J Magn Reson Imaging; 2023 Feb; 57(2):370-386. PubMed ID: 36165348
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric
Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
[TBL] [Abstract][Full Text] [Related]
17. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging as biomarker for treatment response and outcome in breast cancer.
van Geel JJL; de Vries EFJ; van Kruchten M; Hospers GAP; Glaudemans AWJM; Schröder CP
Ther Adv Med Oncol; 2023; 15():17588359231170738. PubMed ID: 37223262
[TBL] [Abstract][Full Text] [Related]
19. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
Kitajima K; Miyoshi Y
Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]